Statements (26)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
nonsteroidal anti-inflammatory drug
|
| gptkbp:ATCCode |
M01AH04
|
| gptkbp:CASNumber |
198470-85-8
|
| gptkbp:chemicalFormula |
C19H18N2O4S
|
| gptkbp:contraindication |
history of allergic reaction to NSAIDs
hypersensitivity to sulfonamides |
| gptkbp:developedBy |
gptkb:Pharmacia
|
| gptkbp:eliminationHalfLife |
22 minutes (parecoxib), 8 hours (valdecoxib)
|
| gptkbp:excretion |
urine
feces |
| https://www.w3.org/2000/01/rdf-schema#label |
parecoxib
|
| gptkbp:IUPACName |
(6-methoxy-2-naphthyl)-N-methylpropanamide
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:marketedAs |
gptkb:Pfizer
|
| gptkbp:metabolism |
hepatic
|
| gptkbp:molecularWeight |
370.4 g/mol
|
| gptkbp:pregnancyCategory |
gptkb:C_(Australia)
|
| gptkbp:prodrugOf |
gptkb:valdecoxib
|
| gptkbp:routeOfAdministration |
intramuscular
intravenous |
| gptkbp:sideEffect |
nausea
headache injection site reaction |
| gptkbp:usedFor |
pain management
|
| gptkbp:bfsParent |
gptkb:nonsteroidal_anti-inflammatory_drug
|
| gptkbp:bfsLayer |
6
|